Market cap
$37 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 34.46 | -- | -- |
| EBIT | 0.00 | -41.14 | -23.11 | -4.07 | -196.42 |
| Net Profit | -- | -- | -23.01 | -13.29 | -204.37 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-21 | Dec-20 | Dec-19 |
| EBIT-Margin
| -7,907.69 | -7,907.69 | -4,370.33 | -5,650.37 | -13,702.37 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -93.22 | -69.99 | -105.78 | -103.21 | -70.67 |
| Return on Capital
| -84.83 | -70.81 | -86.03 | -98.94 | -69.51 |
| Return on Assets
| -68.09 | -52.91 | -67.80 | -78.64 | -57.84 |
| Debt to Equity (x)
| -- | -- | 0.39 | 0.04 | 0.05 |
Profitability
ROCE
-86.03
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
-86.03
|
-98.94
|
-69.51
|
-40.98
|
-58.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-105.78
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
-105.78
|
-103.21
|
-70.67
|
-41.00
|
-29.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-67.80
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
-67.80
|
-78.64
|
-57.84
|
-36.35
|
-23.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-4,370.33
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
-4,370.33
|
-5,650.37
|
-13,702.37
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-4,448.19
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
-4,448.19
|
-4,861.99
|
-11,405.69
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
0.34
--
Year on year growth in net sales
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
0.34
|
1.53
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-4.00
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
-4.00
|
-4.36
|
-2.93
|
-38.30
|
-83.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-23.01
--
Year on year growth in profit after tax
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
-23.01
|
-7.88
|
-1.59
|
-15.87
|
-107.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.39
--
Total debt / Net worth
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
0.39
|
0.04
|
0.05
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
5.21
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
5.21
|
2.59
|
1.80
|
6.40
|
11.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
5.16
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
5.16
|
2.55
|
1.77
|
6.35
|
11.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
407.33
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
407.33
|
1,135.21
|
2,901.42
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.02
--
Sales / Average Total Assets
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
0.02
|
0.02
|
0.01
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
2,285.78
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
2,285.78
|
4,166.86
|
9,966.48
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|